A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ETC-1002 at Doses Above 120 mg/Day in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Mar 2013
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Esperion Therapeutics
- 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
- 12 Apr 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 12 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.